Alphavirus vectors have emerged as a promising strategy for the development of cancer vaccines and gene therapy applications. In this study, we used the replication-defective vaccine vector SIN replicon particles from a new packaging cell line (PCL) to develop SIN replicon particles encoding calreticulin (CRT) linked to a model tumor antigen, human papillomavirus type 16 (HPV16) E7 protein. The linkage of CRT to E7 in SIN replicon particles resulted in a significant increase in E7-specific CD8 þ T-cell precursors and a strong antitumor effect against E7-expressing tumors in vaccinated mice. SINrep5-CRT/E7 replicon particles enhanced presentation of E7 through the major histocompatibility complex (MHC) class I pathway by infecting dendritic cells (DCs) directly and pulsing DCs with lysates of cells infected by SINrep5-CRT/E7 replicons. Vaccination of immunocompromised (BALB/c nu/nu) mice with SINrep5-CRT/E7 replicon particles also generated significant reduction of lung tumor nodules, suggesting that antiangiogenesis may contribute to the antitumor effect of SINrep5-CRT/E7 replicon particles. Furthermore, SINrep5-CRT/E7 replicon particles generated long-term in vivo tumor protection effects and antigen-specific memory immunities. We concluded that the CRT strategy used in the context of SIN replicon particles facilitated the generation of a highly effective vaccine for cancer prophylaxis and immunotherapy.
Introduction
Calreticulin (CRT) is an abundant 46 kDa Ca 2 þ -binding protein located in the endoplasmic reticulum (ER). 1 The protein has been shown to associate with peptides delivered into the ER by transporters associated with antigen processing (TAP-1 and TAP-2) 2 and with major histocompatibility complex (MHC) class I-b2 microglobulin molecules to aid in antigen presentation. 3 Previous studies have shown that CRT can be complexed with peptides in vitro to elicit peptide-specific CD8 þ T-cell responses through exogenous administration. 4 In addition, peptide-bound CRT purified from tumor extracts has been shown to elicit an antitumor effect specific to the source tumor. 4 Our previous work showed that plasmid DNA based cancer therapy using CRT linked to a tumor antigen, human papillomavirus type 16 (HPV16) E7 had promising effects in treating tumors through combining antigen-specific immunotherapy and antiangiogenesis. 5 However, the concern exists that with a CRT/E7 DNA vaccine, HPV-16 E7 may integrate into the host genome and disrupt cell cycle regulation by binding to the tumor suppressor gene -pRB -in the nuclei. 6 In addition, plasmid DNA vaccines remain an relatively unproven strategy in larger animals, including humans.
Alphavirus vectors, such as those derived from Sindbis virus 7, 8 and Semliki Forest virus, 9, 10 have become a promising strategy for the development of vaccines and gene therapies because of their high levels of RNA replication and gene expression in cells, their inherent stimulation of the innate immune response, an ability to infect a variety of diverse cell types, and the relative ease of manipulating cDNA clones for transcription of vectors and infectious viral RNA. 11, 12 The general strategy for construction of alphavirus-based expression vectors has been to substitute the viral structural protein genes with a heterologous gene, while preserving transcriptional control via the highly active subgenomic RNA promoter. 7, 13 These vectors are self-replicating in cells and may be administered as RNA, DNA, or infectious propagationincompetent virus like particles, termed replicon particles. As alphavirus vectors eventually trigger apoptosis of transfected cells, 14 they do not raise the concern associated with DNA integration into the host genome. This is particularly important for vaccines targeting proteins that are potentially oncogenic, such as the HPV E6 and E7. In addition, alphavirus-based vaccines have been utilized in the many diseases such as bacterial infection, 15 malignant tumors, 16, 17 and viral encephalitis. 18 Alphavirus replicon particle vaccines typically are produced using trans-complementing defective helper constructs that separately express the capsid and envelope glycoproteins from distinct cassettes as a means to minimize the risk of RNA recombination leading to the formation of replication-competent virus (RCV). These defective helper constructs may be transiently transfected into cells as in vitro transcribed RNA, 19 or alternatively transcribed in vivo from DNA cassettes contained in stable alphavirus replicon packaging cell lines (PCL). The availability of such PCL may eventually allow for largescale vector production that is useful in vaccine applications.
Human papillomaviruses, particularly HPV16, are associated with the majority of cervical cancers. 20 HPV16 E7 protein is expressed in most HPV-containing cervical cancers, and is important in the induction and maintenance of cellular transformation. Therefore, vaccines targeting E7 protein may be useful for the prevention and treatment of HPV-associated cervical cancer. In this report, we have observed that SIN replicon particles encoding CRT linked to HPV16 E7 can generate an impressive antitumor effect against HPV16 E7-expressing murine tumors through the enhancement of E7-specific CD8 þ T-cell-mediated immune responses and antiangiogenesis. We also demonstrated that SINrep5-CRT/E7 replicon particles vaccine generated long-term in vivo tumor protection effects and antigen-specific memory immunity. SIN replicon particles encoding CRT to an antigen gene could provide a promising approach to cancer vaccine and immunotherapy.
Materials and methods

Cell lines
The PCL (987dlsplit clone 24) has been described previously, 21 and was grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), antibiotics, and G418. The production and maintenance of TC-1 cells have been described previously. 22 On the day of tumor challenge, TC-1 cells were harvested by trypsinization, washed twice with Hanks' buffered salt solution (HBSS), and finally resuspended in 1 Â HBSS to the designated concentration for injection. Baby hamster kidney (BHK21) cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD) and grown in Glasgow minimal essential medium (MEM) supplemented with 5% FBS, 10% tryptose phosphate broth, 2 mM glutamine, and antibiotics.
Plasmid DNA constructs The Sindbis virus RNA replicon vector, SINrep5, has been described previously, 23 and was kindly provided by C Rice (Washington University School of Medicine, St Louis, MO). For the generation of SINrep5-CRT and SINrep5-CRT/E7, DNA fragments encoding CRT and CRT/E7 were isolated by cutting pcDNA3-CRT and pcDNA3-CRT/E7, 5 respectively, with XbaI and PmeI restriction enzymes, followed by gel recovery of the digested products. These isolated DNA fragments were further cloned into the corresponding XbaI and PmeI sites of the SINrep5 vector to generate SINrep5-CRT and SINrep5-CRT/E7 constructs. The accuracy of these constructs was confirmed by DNA sequencing.
In vitro RNA preparation
The generation of RNA transcripts from SINrep5-CRT, SINrep5-E7, SINrep5-CRT/E7 and SINrep5 were performed according to a protocol described previously. 24.- Briefly, SpeI was used to linearize DNA templates. RNA replicons were transcribed in vitro and capped using SP6 RNA polymerase and capping analog from an in vitro transcription kit (Life Technologies, Rockville, MD), according to the vendor's manual. After synthesis, DNA was removed by digestion with DNase I. Synthesized RNA was then purified by precipitation. RNA concentration was determined by optical density measured at 260 nm. The integrity and quantity of RNA transcripts were further checked by denaturing gel electrophoresis. The protein expression of the transcripts was characterized by enzyme-linked immunosorbent assay (ELISA) to detect the E7 protein concentrations of various RNAtransfected BHK21 cells, using a Cell-Porator electroporation system (Life Technologies) according to the vendor's manual.
Generation of SINrep5 replicon particles and determination of the vector titer SINrep5 replicon particles were made according to a previously described protocol by Polo et al. 21 Briefly, 4 mg of in vitro-synthesized mRNA was electroporated into 1 Â 10 7 PCL cells. The PCL cells were incubated in 23 ml of DMEM supplemented with 10% FBS, antibiotics, and G418 at 5% CO 2 , 371C. After 72 h, culture supernatants were collected. The titer of SINrep5 replicon particles in clarified PCL culture supernatants was determined by infection of naive BHK21 monolayers, followed by indirect E7 immunofluorescence staining 25 with serial dilution and quantitation of the total number of greenstained cells per well at each dilution. Vector titer is designated as infectious units (IU) per milliliter, and represents the population of functional particles.
Mice Six-to 8-week-old female C57BL/6 or nude (BALB/c nu/ nu) mice were purchased and kept in the animal facility of the National Taiwan University Hospital (Taipei, Taiwan). All animal procedures were performed according to approved protocols, and in accordance with recommendations for the proper use and care of laboratory animals.
Infection of dendritic cells with SIN replicon particles
Bone marrow-derived DCs were generated from bone marrow cells of mice in the presence of granulocytemacrophage colony-stimulating factor (GM-CSF) as described previously. 26. Dendritic cells infected with various SINrep5 particles were done in suspension (2 Â 10 5 cells, multiplicity of infection (MOI) ¼ 50) with a total volume of 500 ml of serum-free media as described previously. 27 After 1-h incubation with continuous rocking, 500 ml of media containing GM-CSF was added. The SINrep5-infected DCs were cultured for 24 h and then used for further experiments.
Intracytoplasmic cytokine staining and flow cytometry analysis Intracytoplasmic cytokine staining and flow cytometry analysis were performed as described previously. 28 In brief, mice (five per group) were vaccinated with various SINrep5 replicon particles (5 Â 10 6 IU/mouse) via intramuscular administration. Naive mice served as negative controls. Splenocytes from vaccinated mice were collected 7 days after vaccination and incubated either with the E7 peptide (amino acids (aa) 49-57, RAHYNIVTF) containing the MHC class I epitope 29 (to detect E7-specific CD8 þ cytotoxic T-cell precursors) or with the E7 peptide (aa 30-67, DSSEEEDEIDGPAGQAEPDRAHY-NIVTFCCKCDSTLRL containing the MHC class II epitope 30 (to detect E7-specific CD4 þ T helper cell precursors) for 20 h. Cells were subjected to intracellular cytokine staining, using a Cytofix/Cytoperm kit (PharMingen, San Diego, CA), according to the manufacturer's instructions. Analysis was carried out on a FACScan with CellQuest software (Becton Dickinson Immunocytometry System, Mountain View, CA).
In another experiment, mice (five per group) were vaccinated intramuscularly with SINrep5-CRT/E7 replicon particles (5 Â 10 6 IU/mouse). Splenocytes from these vaccinated mice were collected 7, 14, 21, 30, and 60 days after vaccination and incubated either with the E7 peptide (aa 49-57), and then with intracellular cytokine staining, and analyzed as described earlier.
In the third experiments, we used an E7-specific CD8 þ T-cell line (kindly provided by Dr TC Wu, Johns Hopkins University, Baltimore, MD) as effector cells. Various SINrep5 replicon particle-infected DCs were used as antigen-presenting cells (APCs) as described earlier. Then, the E7-specific CD8 þ T cells were cocultured with these SINrep5-infected DCs for 20 h. Cells were subjected to intracellular cytokine staining and analysis was carried out on a FACScan with CellQuest software as described earlier.
Enzyme-linked immunosorbent assay
Anti-HPV16 E7 antibodies in the sera from various SINrep5 replicon particles vaccinated mice (five per group) were determined by a direct ELISA, as described previously. 31 The ELISA plate was read with a standard ELISA reader at 450 nm.
In another experiment, mice (five per group) were vaccinated intramuscularly with SINrep5-CRT/E7 replicon particles (5 Â 10 6 IU/mouse). Sera from these vaccinated mice were collected 7, 14, 21, 30, and 60 days after vaccination. The anti-E7 antibodies of the sera were detected as described earlier.
In the third experiment, the quantity of E7 protein in cell lysates from BHK21 cells infected with SINrep5-E7 or SINrep5-CRT/E7 replicon particles was determined by an indirect ELISA method as described previously. 32 Briefly, 1 Â 10 7 BHK21 cells were infected with 5 Â 10 7 IU of SINrep5, SINrep5-E7, SINrep5-CRT, or SINrep5-CRT/ E7 particles. The transfected BHK21 cells were collected 40-44 h after infection. The quantity of E7 protein in cell lysates from transfected BHK21 cells was determined by ELISA with a standard ELISA reader at 450 nm. The quantity of E7 protein of cell lysates was then calculated and determined by comparison with the standardized E7 protein.
In vivo tumor protection experiments
For the tumor protection experiment, mice (five per group) were immunized intramuscularly with SINrep5-E7, SINrep5-CRT, SINrep5-CRT/E7, or SINrep5 with no insert replicon particles (5 Â 10 6 IU/mouse). One week after vaccination, mice were subcutaneously challenged with 1 Â 10 4 TC-1 cells/mouse in the right leg. Mice were monitored for evidence of tumor growth by palpation and inspection twice a week until they were killed on day 60.
In vivo tumor treatment experiments C57BL/6 mice or nude mice (five in each group) were intravenously challenged with TC-1 tumor cells per mouse (1 Â 10 4 TC-1 for C57BL/6 mice and 5 Â 10 4 TC-1 for nude mice) via the tail vein on day 0. Two days after tumor challenge, mice were treated intramuscularly with SINrep5-E7, SINrep5-CRT, SINrep5-CRT/E7, or SINrep5 control replicon particles (5 Â 10 6 IU/mouse) every 7 days until killed. Mice were killed on day 28 after tumor challenge. The number of pulmonary tumor nodules on the surface of the lungs in each mouse was determined by experimenters blinded to sample identity.
In vivo antibody depletion experiments
The procedure for in vivo antibody depletion has been described previously. 5, 31 Briefly, mice were vaccinated intramuscularly with SINrep5-CRT/E7 replicon particles (5 Â 10 6 IU/mouse). Depletions were started on day 7 after immunization and mice were challenged with TC-1 tumor cells (1 Â 10 4 per mouse) on day 14 after immunization. Monoclonal antibody (MAb) GK1.5 33 was used for CD4 þ cell depletion, MAb 2.43 34 was used for CD8 þ cell depletion, and MAb PK136 35 was used for NK1.1 þ cell depletion. Flow cytometry analysis revealed that 99% of the appropriate lymphocyte subsets were depleted while maintaining normal levels of other subsets. Depletion was terminated on day 40 after tumor challenge.
In vivo antigen rechallenging experiments
To evaluate the in vivo antigen-specific effector and memory CD8 þ T-cell responses in the SINrep5-CRT/ E7 replicon particle immunized mice, mice vaccinated at different times courses (7, 14, 21, 30 , or 60 days after immunization) were rechallenged with 1 Â 10 7 IU of Vaccinia-E7 (kindly provided by Dr TC Wu, Johns Hopkins University, Baltimore, MD) intraperitoneally. The mice were killed 7 days after intraperitoneal Vaccinia-E7 injection. The preparation of splenocytes, surface marker and intracellular cytokine stainings, and flow cytometry analysis were performed as described earlier.
In vivo angiogenesis assay using matrigel In vivo angiogenesis was assessed using the matrigel plug assay with a protocol similar to that described previously. 5, 36 Mice were immunized with various SINrep5 replicon particles (5 Â 10 6 IU/mouse) of plasmid without insert, E7, CRT, or CRT/E7 on day 0 and day 7. Matrigel (Becton Dickinson and Co., Franklin Lakes, NJ) was mixed with heparin (final concentration of 50 U/ml) and bFGF (final concentration of 10 ng/ml) at 41C. A total of 0.5 ml/mouse of this matrigel mixture was injected subcutaneously into the abdominal midline of vaccinated or naive mice on day 7. Naive mice injected with matrigel mixed with heparin and bFGF served as a positive control and naive mice injected with matrigel alone were used as a negative control. Mice were euthanized on day 16. The matrigel plugs were resected from surrounding connective tissues. Half of the matrigel plugs were fixed in 10% formaldehyde, embedded in paraffin, sectioned, and stained with hematoxylin and eosin stains to calculate microvessel density (MVD). In each section, the five most vascular areas were chosen. Microvessel counts were obtained at Â 400, and the mean number in the five fields for the matrigel plugs was calculated and referred to as the MVD count. The remaining half of the matrigel plugs were assayed for hemoglobin content, according to the manufacturer's instructions (Human GmbH, Wiesbaden, Germany).
Statistical analysis
All data are expressed as mean7s.e.m. are representative of at least two different experiments. Data for tumor treatment experiments were evaluated by analysis of variance (ANOVA). Comparisons between individual data points were made using a Student's t-test. In the tumor protection experiment, the principal outcome of interest was time to development of tumor. The event time distributions for different mice were compared by use of the method of Kaplan and Meier and by use of the logrank statistic. Differences were considered significant if Po0.05.
Results
SINrep5-CRT/E7 replicon particles enhances E7-specific CD8
þ T cells and antibodies responses To compare the immunogenicity of SINrep5-E7 vaccines with or without a CRT fusion element, we determined the quantity of E7-specific CD4 þ and CD8 þ T-cell precursors, and anti-E7 antibodies in mice vaccinated with various SINrep5 replicon particles, using intracellular cytokine staining and ELISA as described in Materials and methods. As shown in Figure 1a , mice vaccinated with SINrep5-CRT/E7 replicon particles generated the greatest number of E7-specific CD8 þ T precursors compared with the other vaccine groups (Po0.001, oneway ANOVA). SINrep5-CRT/E7 replicon particles generated a significant, 16-fold increase in the number of E7-specific CD8
þ T-cell precursors compared with the levels generated by SINrep5-E7 replicon particles (321.5714.5 vs 20.575.5 per 3.5 Â 10 5 splenocytes, Po0.001, one-way ANOVA). In comparison, the number of E7-specific CD4 þ T-cell precursors generated by the different SIN replicon particles did not reveal any significant differences (Figure 1b and c) . We also found that the titers of anti-E7 antibody generated by SINrep5-CRT/E7 replicon particles was higher than those generated by the other groups (Po0.001, one-way ANOVA) (Figure 1d ). Our results indicated that fusion of E7 to CRT was required for enhancement of CD8 þ T-cell activity, because CRT mixed with E7 did not generate comparable levels of CD8 þ T-cell activity ( Figure 1a ).
Vaccination with SINrep5-CRT/E7 replicon particles enhances protection of mice against the growth of TC-1 tumors To determine whether vaccination with the various SIN replicon particles protected mice against E7-expressing tumors, in vivo tumor protection experiments were performed. As shown in Figure 2a , all of the mice receiving SINrep5-CRT/E7 particles remained tumor free 60 days after TC-1 challenge. In contrast, all of the unvaccinated mice, as well as control mice receiving SINrep5 with no insert, E7, CRT, or CRT mixed with E7 (CRT þ E7), developed tumors within 14 days after TC-1 challenge (Po0.01, log-rank test). These results indicated that a fusion of E7 to CRT provides the highest level of antitumor immunity.
Cytotoxic CD8
þ T cells, helper CD4 þ T cells, and natural killer cells are essential for the antitumor effect of SINrep5-CRT/E7 replicon particles To determine the subset of lymphocytes that is important for the rejection of E7-positive tumor cells, we performed in vivo antibody depletion experiments. As shown in Figure 2b , all of naı¨ve mice and mice depleted of CD8 þ T cells grew tumors within 14 days after tumor challenge (Po0.01, log-rank test). Eighty percent of mice depleted of CD4 þ T cells or NK1.1 þ cells developed tumors within 60 days of tumor challenge, although the tumor growth in these two groups was slower than in the CD8-depleted mice. The results of in vivo Ab depletion experiments suggested that cytotoxic CD8 þ T cells, helper CD4
þ T cells, and NK cells are all important for the antitumor immunity generated by the SINrep5-CRT/ E7 replicon particles.
Vaccination with SINrep5-CRT/E7 replicon particles eradicates established E7-expressing tumors in the lungs
To determine the therapeutic potential of the SINrep5-CRT/E7 vaccine, C57BL/6 mice were challenged with TC-1 tumor cells (1 Â 10 4 per mouse) by tail vein injection to establish TC-1 tumors in the lungs. 37 This model provides a more quantitative assessment of antitumor effects than the subcutaneous model. Mice treated with SINrep5-CRT/E7 replicon particles 2 days after tumor challenge exhibited a significantly lower mean number of pulmonary nodules than mice vaccinated with SINrep5-E7 replicon particles ((1.070.7 vs 68.575.5, Po0.01, one-way ANOVA) (Figure 3b ). We also noted that the mean number of pulmonary tumor nodules in mice vaccinated with SINrep5-CRT replicon particles was lower than that in mice vaccinated with SINrep5-E7 replicon particles (27.573.5 vs 68.575.5, Po0.01, oneway ANOVA).
We further tested the ability of SINrep5 replicon particles to eradicate established E7-expressing tumors in the lungs of nude mice. As shown in Figure 3b , nude mice treated with SINrep5-CRT/E7 or CRT replicon particles 2 days after tumor challenge exhibited a significantly lower mean number of pulmonary nodules than mice vaccinated with SINrep5-E7 replicon particles (17.774.0 for CRT/E7, 16.072.0 for CRT, 53.774.7 for E7, P ¼ 0.001, one-way ANOVA). The mean number of pulmonary nodules was indistinguishable between the CRT/E7 and CRT groups.
Our results showed that SINrep5-CRT/E7 replicon particles could control TC-1 tumor growth in both immunocompetent (C57BL/6) mice and immunocompromised (BALB/c nu/nu) mice. The CRT/E7 group generated significantly higher numbers of E7-specific CD8 þ T cell precursors and higher titers of anti-E7 Ab than those in the other groups. The numbers of E7-specific CD4 þ T cell precursors were similar in the naïve and each vaccinated groups.
Enhanced presentation of E7 through the MHC class I pathway in DCs cells infected with SINrep5-CRT/E7 replicon particles directly and in dendritic cells (DCs) pulsed with lysates of cells infected by SINrep5-CRT/E7 replicon particles indirectly We explored potential explanations for the observed increase in E7-specific CD8 þ T-cell precursors in mice vaccinated with SINrep5-CRT/E7 replicon particles. One potential explanation is that there was direct enhancement of MHC class I presentation of E7 in cells expressing CRT/E7. We therefore performed intracellular cytokine staining assays using bone marrow-derived DCs infected with the various SINrep5 replicon particles as target cells and an H-2 Db-restricted E7-specific CD8 þ T-cell line as effector cells. As shown in Figure 4a , DCs infected with SINrep5-CRT/E7 replicon particles generated significantly higher numbers of IFN-g-secreting E7-specific CD8 þ T cells (108.577.5) compared with mice vaccinated with SINrep5-E7 replicon particles (15.075.0) did. Our results suggested that SINrep5-CRT/E7 replicon particles could infect the DCs directly and present E7 antigen through the MHC class I pathway to CD8 þ T cells more efficiently than DCs infected with SINrep5-E7 replicon particles.
Another potential mechanism for the observed enhancement of E7-specific CD8
þ T-cell immune responses in vivo is the so-called 'cross-priming' effect, whereby CRT/E7 protein released from cells may be taken up and processed by other APCs via the MHC class I-restricted pathway. We performed CTL assays to characterize MHC class I presentation of E7 in DCs that have taken up apoptotic cells, as described previously. 12 This was modeled by coculturing DCs with various SINrep5 replicon particles infected-BHK21 cell. As shown in Figure 4b , DCs cocultured with SINrep5-CRT/E7 replicon particle-infected BHK21 cells generated a significantly higher percentage of specific lysis than naı¨ve DCs or DCs cocultured with other SINrep5 replicon particles infected BHK21 cells (E/T ratio 27:1, CRT/E7 group 39.074.9, CRT group 4.670.3, E7 group 4.871.0, no insert group 2.971.0, ANOVA, Po0.001). These results indicated that the linkage of CRT to E7 may enhance MHC class I presentation of E7 by DCs when antigen is administered exogenously.
In vivo antiangiogenesis in mice treated with SINrep5-CRT and CRT/E7 replicon particles To provide a more quantitative assessment of antiangiogenesis in C57BL/6 mice treated with the various SINrep5 replicon particles, we examined in vivo angiogenesis using a matrigel assay. Representative H&E stained sections of matrigel samples from different SINrep5 replicon particle vaccine groups are shown in Figure 5a . The mean MVD in matrigel samples from SINrep5-CRT (22.372.5) and CRT/E7 (26.075.3) replicon particles-treated mice was similar and significantly lower than the MVD in matrigel samples from SINrep5 with no insert (112.7712.2) or E7 (117.7711.0) groups (Po0.01, one-way ANOVA) (Figure 5b ). In addition, the hemoglobin contents of matrigel implants from SINrep5-CRT (12.773.0) and CRT/E7 (16.774.2) replicon particle-treated mice were also significantly lower than those from SINrep5 with no insert (53.675.5) and E7 (42.477.9) groups (Po0.01, one-way ANOVA, Figure 5c ). There was no statistically significant difference in the MVD or hemoglobin concentration of the matrigel samples between SINrep5-CRT and CRT/E7 groups (P40.05, one-way ANOVA). These assays revealed that SINrep5-CRT and CRT/E7 replicon particles could generate a similar degree of inhibition of bFGF-and VEGF-induced in vivo angiogenesis.
SINrep5-CRT/E7 replicon particle vaccine generates long-term in vivo tumor protection effects We further tested whether the SINrep5-CRT/E7 replicon particle vaccine could generate long-term protection from the E7-expressing tumor. Mice were immunized with SINrep5-CRT/E7 replicon particles and challenged with TC-1 tumor cells 7, 30 or 60 days after vaccination. As shown in Figure 6 , mice receiving the SINrep5-CRT/E7 replicon particles 7 days before challenge with TC-1 showed 100% of tumor-free 60 days after TC-1 challenge. Sixty percent of mice receiving SINrep5-CRT/E7 replicon particles 30 or 60 days before challenge with TC-1 were still tumor-free 60 days after TC-1 challenge, respectively. Our data revealed that SINrep5-CRT/E7 replicon particle vaccine could protect mice from tumor growth, at least partially, for an extended period after vaccination.
Mice immunized with SINrep5-CRT/E7 replicon particles vaccine maintain long-term immunologic responses
To elucidate why mice immunized with SINrep5-CRT/E7 replicon particles still exhibited antitumor effect 30 and 60 days later, we evaluated if the SINrep5-CRT/E7 replicon particles could induce long-term immunologic responses to reflect their long-term tumor protection effects. Mice were immunized with SINrep5-CRT/E7 replicon particles and the kinetic changes of immunologic responses from 7 to 60 days after immunization were evaluated. As shown in Figure 7a , the numbers of E7-specific CD8 þ T-cell precursors decreased gradually after vaccination from day 7 to day 60. The peak of response of E7-specific CD8 precursors was 7 days after immunization and the numbers of E7-specific CD8 þ T precursors dropped dramatically 21 days after immunization. The numbers of CD8 þ T-cell precursors in vaccinated mice after 21, 30 or 60 days were not higher than those in the naı¨ve group (P40.05, ANOVA). However, E7-specific antibody in the SINrep5-CRT/E7 replicon particle vaccinated mice remained 60 days after immunization. The peak of the anti-E7 Ab titer in vaccinated mice was 30 days after immunization (Figure 7b) .
Our results showed that E7-specific immunologic responses, especially the antibody response, could persist at least 60 days after immunization. However, the timing to the peak of immunologic responses on the number of E7-specific CD8 þ T precursors and the titer of anti-E7 antibodies were different in mice immunized with SINrep5-CRT/E7 replicon particles.
SINrep5-CRT/E7 replicon particle vaccinated mice rapidly expand E7-specific CD8 þ T-cell precursors in response to E7 antigen To evaluate why the numbers of E7-specific CD8 þ T-cell precursors did not correlate with the antitumor effects in mice vaccinated with SINrep5-CRT/E7 replicon particles and challenged 30 and 60 days later, the E7-specific immunologic responses were analyzed following reexposure to the E7 antigen. As shown in Figure 8 , the numbers of E7-specific CD8 þ T-cell precursors in animals rechallenged with Vaccinia-E7 were similar to those in animals not rechallenged Vaccinia-E7 at 7 days after SINrep5-CRT/E7 replicon particles immunization (327.0715.0 vs 321.0714.5, P40.05, one-way ANOVA). However, the numbers of E7-specific CD8 þ T-cell precursors for animals rechallenged with Vaccinia-E7 were significantly higher than those not rechallenged 14, 21, 30, and 60 days after the initial SINrep5-CRT/E7 replicon particle immunizations (296.577.5 vs 102.0717.0 for D14, 262.576.5 vs 23.075.0 for D21, 242.576.5 vs 23.574.5 for D30, 145.076.0 vs 20.574.0 for day 60, one-way ANOVA, Po0.01) (Figure 8 ). Our data showed that E7-specific CD8 þ memory T lymphocytes exist in the mice vaccinated with SINrep5-CRT/E7 replicon particles 30 and 60 days later after immunization and the E7 antigen-specific memory T lymphocytes could proliferate and react soon after a re-encounter with the E7 antigen.
Discussion
In this manuscript, we demonstrate that an SINrep5-CRT/E7 replicon particle vaccine expressing a CRT-E7 fusion, provides significantly enhanced E7-specific CD8 þ T-cell responses compared with a SINrep5-E7 SIN replicon particles vaccine expressing E7 alone. SIN replicon particle infected cells have been reported to readily undergo apoptosis. 28 The enhanced E7-specific CD8 þ T-cell responses by SINrep5-CRT/E7 replicon particles are likely generated through a process whereby apoptotic cells are endocytosed and processed by APCs with MHC class I antigen presentation to CD8 þ T cells. 38, 39 Alternatively, apoptotic cells may release chimeric CRT/E7 protein to be taken up and processed by other APCs via the MHC class I-restricted pathway. 40, 41 Another possibility is that SINrep5 replicon particles might infect APCs such as DCs in vivo directly and then these infected APCs process and present antigen via the MHC class I-restricted pathway. We observed that SINrep5-CRT/E7 replicon particle infected bone marrowderived DCs and these infected DCs can more efficiently induce higher numbers of E7-specific CD8 þ T cells secreting IFN-g than SINrep5-E7 replicon particle infected bone marrow-derived DCs (Figure 4) . Dendritic cells are the most potent APCs and play a major role in the activation of naive and memory T cells. SIN replicon particles generated with a modified E2 glycoprotein have been successfully used to deliver genes of interest into DCs to form a DC-based vaccine and generate potent immune responses in vaccinated mice, 27 as we observed. We expect that the combination of the CRT fusion strategy with the convenience of generating SIN replicon particles from the stable PCL may potentially improve the efficiency of antigen delivery into DCs and enhance the development of dendritic cell-based vaccines for immunotherapy.
The effector mechanisms of antitumor effect vary among different types in cancer vaccines. We have tested the CRT strategy in a mammalian expression DNA vector (pcDNA3) 5 and self-replicating SINrep5 viral vector. We found that each vaccine enhanced E7-specific CD8 þ Tcell-mediated immune responses and antitumor effects, although an interesting difference emerged regarding the effector cells that were essential for the antitumor effect. Our studies have demonstrated that CD8 þ T cells were important in both the vectors we tested, whereas CD4 þ T cells and NK cells were essential only for the antitumor effect generated by the SINrep5-CRT/E7 replicon particle-based vaccine. Although CD4 þ T cells were important for the antitumor effect generated by the CRT/E7 SIN replicon particle-based vaccine, the vaccine did not actively induce E7-specific CD4 þ T cells, suggesting that CD4 þ T cells may indirectly contribute to the antitumor effect. We also found that the percentages of NK cells increased for all of the SINrep5 replicon particle vaccine groups, regardless of the heterologous gene expressed (data not shown). This phenomenon could not be observed in the naked DNA vaccinated groups. It might The matrigel plugs were fixed, embedded, sectioned, and stained to calculate MVD as described in the Materials and methods. Note: The mean MVD in matrigel samples from SINrep5-CRT and CRT/E7 replicon particles-treated mice were similar and significantly lower than the mean MVD in matrigel samples from SINrep5 with no insert and E7 groups. (c) Matrigel hemoglobin contents for SINrep5 replicon particles vaccines. Note: The hemoglobin contents of matrigel implants from SINrep5-CRT and CRT/E7 replicon particles-treated mice were significantly lower than those from SINrep5 with no insert and E7 groups. There was no statistically significant difference in hemoglobin content of the matrigel samples between SINrep5-CRT and CRT/E7 replicon particles groups.
explain why the NK cells are also essential in the antitumor effects of SINrep5-CRT/E7 replicon particles vaccine, but not essential in those of naked CRT/E7 vaccine. Neither CD4 þ T cells nor NK cells are essential for the antitumor effects of naked CRT/E7 DNA vaccine because depletion of CD4 þ T cells or NK cells did not lead to any significant loss in antitumor effect in mice vaccinated with pcDNA3-CRT/E7. 5 Thus, different vaccine formats encoding the same construct may activate different subsets of effector cells in the vaccinated host and have different immunologic or antitumor mechanisms.
SINrep5-CRT/E7 replicon particles appeared to generate antitumor effects through an antiangiogenic pathway. We observed that treatment of T-cell-depleted nude mice with SINrep5-CRT or CRT/E7 replicon particles generated comparable T-cell-independent antitumor effects (Figure 3d) . Meanwhile, intratumoral microvessel densities and matrigel assays in nude mice revealed that SINrep5-CRT/E7 and CRT alone replicon particles generated a stronger antiangiogenic effect than SINrep5-E7 and no insert replicon particles (Figure 4) . However, there may be additional activity of non-T-cell effectors (i.e., NK cells, neutrophils, and macrophages) or cytokines (i.e., interleukin-12, INF-g) in nude mice contributing to the antitumor effects. Similar antitumor effects were also found in the naked CRT and CRT/E7 DNAvaccinated nude mice in our previous study. 5 These above-mentioned effector cells and cytokines may affect the antitumor effect and angiogenesis. It would be interesting in the future to investigate characteristics of cytokine production and non-T-cell effectors related to vaccination with SINrep5-CRT/E7 or CRT replicon particles and examine their role in the antitumor effect and antiangiogenesis.
Antigen-specific antibody could be enhanced by SINrep5 replicon particle vaccines. We observed that titers of E7-specific Ab were significantly enhanced by SINrep5-CRT/E7 vaccination and could persist for more than 60 days after vaccination, despite a lack of enhancement of E7-specific CD4 þ T helper cells (Figure 1 ). Antibodytargeted approaches for immunotherapy have been demonstrated in some tumors such as the breast cancer model with the HER-2/neu antigen, 42 colon cancer model with the b-hCG, 43 colon cancer vaccine against CEA, 44 or B cell lymphoma vaccines including against immunoglobulin idiotype. 45 SINrep5-CRT/E7 replicon particles could provide a long period of antibody (for more than þ T-cell precursors. The mice were immunized, and their splenocytes and serum samples were prepared, stained, analyzed were performed as described in the Materials and methods. Note: The numbers of E7-specific CD8 þ T cell precursors decreased gradually after vaccination from day 7 to day 60. The peak day of number of E7-specific CD8 þ T precursors was on 7 days after immunization. (b) E7-specific antibody responses by enzyme-linked immunosorbent assay. Note: The titers of E7-specific Ab increased gradually after vaccination. The peak of the titer of E7-specific Ab was on 30 days after SINre5-CRT/E7 replicon particles immunization. The titers of E7-specific Abs in SINrep5-CRT/E7 group even after 60 days of immunization was persistently higher than those in naïve mice. 60 days after vaccination in mice) and this chimeric CRT vaccine strategy-induced antibody may be used to target other antigen-specific tumor models.
SINrep5-CRT/E7 replicon particle vaccines also induced long-term protective antitumor effects and antigenspecific T-cell memory responses. In this study, SINrep5-CRT/E7 replicon particles generated antigen-specific memory effects. Our results showed that SINrep5-CRT/ E7 replicon particles induced long-lived CTL memory responses that were capable of rapidly responding to and protecting against a subsequent tumor challenge ( Figures  6 and 8) . The aim of vaccination protocols is the induction of efficient long-term immune memory. Therefore, it is important to understand the factors governing the formation and maintenance of long-term tumorspecific T-cell memory. Antigen-specific memory T cells differ from naive cells in having less stringent requirements for activation, being less dependent on co-stimulation, and requiring lower Ag-concentrations for activation. 46, 47 As a consequence, memory cells exhibit a more rapid and vigorous response to Ag-stimulation than do their naı¨ve counterparts. SINrep5 replicon particle vaccines have the potential to be developed as preventive cancer vaccines.
Although replication-defective viral vectors such as SIN replicon particles offer the possibility of high-level antigen expression, one potential limitation is their intrinsic inability to enhance antigen processing and presenting procedures. In this study, we successfully utilized CRT in the context of SIN replicon particle vectors to facilitate antigen processing and presentation in vivo, resulting in a significantly enhanced E7-specific CD8 þ T-cell responses and antitumor effect. Thus, the combination of the CRT strategy with a vector platform amenable to scale-up using stable PCL represents an innovative approach for generating a safe, potent vaccine in high quantities and provides several advantages over other vaccine approaches. Compared with naked nucleic acid vaccines, SIN replicon particles are capable of delivering antigen to higher percentage of cells. The linkage of antigen to CRT further enhances the potency of this vaccine. Furthermore, SIN replicon RNA does not have the possibility to integrate into the host genome, which is a potential concern with naked DNA vaccines or some DNA-based viral vectors. Production of SIN replicon particles that are free of RCV maximizes the opportunity for vaccine potency while minimizing risk factors associated with replication-competent viral vectors. Stable PCL provide such a platform and should be applicable to a variety of alphavirus vectors, including Sindbis-and Semliki Forest virus-derived replicon vectors.
In summary, our results revealed that the combined use of the CRT strategy along with an efficient method of producing safe SIN replicon particle preparations was effective in generating potent antigen-specific immune responses, antiangiogenic effect and a strong antitumor effect. These strategies may also be applied to other cancer systems and infectious diseases. CRT/E7 D60 Figure 8 Antigen rechallenging experiments in SINrep5-CRT/E7 replicon particles vaccinated mice. To evaluate the antigen-specific effector and memory CD8 þ T-cell responsse in the SINrep5-CRT/E7 replicon particles vaccinated mice, vaccinated mice at different time courses (7, 14, 21, 30 , or 60 days after immunization) were rechallenged with 1 Â 10 7 IU of Vaccinia-E7 intraperitoneally. The preparation of splenocytes, surface marker and intracellular cytokine stainings and flow cytometry analysis were performed as described in the Materials and methods. Note: The numbers of E7-specific CD8 þ T cell precursors when rechallenged with Vaccinia-E7 were significantly higher than those without rechallenged E7 antigen at 14, 21, 30, and 60 days after SINrep5-CRT/E7 replicon particles immunization. The numbers of E7-specific CD8 þ T cell precursors after immunizing with SINrep5-CRT/E7 replicon particles 7 days were similar regardless with or without rechallenged Vaccinia-E7 or not.
